Renalytix reported $2.3 million in revenue, including $2.1 million from testing services and $0.2 million from pharmaceutical services. The loss before tax was $44.9 million, which included impairment of intangibles of $10.2 million and fair value adjustments to convertible debt of $3.75 million. Total assets were $7.3 million, and cash and cash equivalents amounted to $4.7 million.

Renalytix reported $0.5 million in revenue for Q3 2024, a decrease from $0.7 million in the same period last year. The company's operating expenses decreased to $6.5 million from $11.0 million year-over-year, and the net loss was $7.7 million, compared to $12.1 million in the prior year period. Cash and cash equivalents totaled $4.7 million as of March 31, 2024.

Renalytix reported $0.7 million in revenue for the second quarter of fiscal year 2024, a decrease compared to the $1.192 million reported in the same period last year. The company's net loss was $8.5 million, an improvement from the $10.4 million loss in the prior year. Operating expenses were reduced to $8.9 million from $10.1 million in the prior year. Cash and cash equivalents totaled $5.6 million as of December 31, 2023.